Protagenic Therapeutics (PTIX) Financials

$0.95

$-0.05 (-5.00%)

As on 04-Sep-2026 15:21EDT

Market cap

$2 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

3.3

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	0.04	0.05	0.03	0.00	--	0.00
Gross Profit	-0.04	-0.05	-0.03	0.00	--	0.00
Operating Expenses	5.81	5.70	4.50	3.56	4.14	2.55
Operating Profit (EBIT)	-5.83	-5.70	-4.53	-3.56	-4.14	-2.55
Other Income	--	--	--	--	--	--
Profit before Tax	-5.16	-5.53	-5.00	-3.56	-4.52	-2.55
Provision for Tax	--	--	0.00	0.05	0.46	0.25
Profit after Tax (Net Income)	-5.16	-5.53	-5.00	-3.56	-4.52	-2.55
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-4.52	-2.55

Liabilities ($ Mln)	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Shareholder's Funds	-2.39	1.01	3.67	6.92	9.94	-1.15
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	--	--	1.01	0.32	1.37
Current Liabilities	6.82	0.94	0.66	1.12	0.80	0.66
Total Liabilities	2.13	1.96	4.32	8.04	11.06	0.88

Assets ($ Mln)	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Non-Current Assets	-0.17	0.07	0.12	0.00	--	--
Current Assets	2.30	1.88	4.20	8.04	11.06	0.88
Total Assets	2.13	1.96	4.32	8.04	11.06	0.88
Total Debt*	3.16	--	--	0.34	0.32	1.37
Net Current Assets	--	0.94	3.54	6.92	10.26	0.22

Cashflow ($ Mln)	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Cash From Operating Activities	-4.14	-4.22	-3.70	-1.99	-2.80	-1.35
Cash Flow from Investing Activities	0.94	2.80	4.78	1.60	-9.91	-9.91
Cash from Financing Activities	4.51	1.96	--	--	12.58	1.22
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Adjusted EPS ($)	-2.66	-0.85	-1.13	-0.82	-0.26	-0.99
Cash EPS ($)	-2.66	-0.84	-1.13	-0.82	-0.26	-0.99
Adjusted Book Value ($)	--	0.16	0.83	1.60	0.58	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	-2.14	-0.65	-0.84	-0.46	-0.16	-0.53
Free Cash Flow per Share ($)	-2.14	-0.65	-0.87	-0.46	-0.16	-0.53

Profitability Ratios	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
ROCE (%)	-580.54	-236.05	-91.49	-40.59	-86.28	3,893.10
ROE (%)	747.54	-236.05	-94.47	-42.18	-102.89	285.72
ROA (%)	-252.26	-175.98	-80.90	-37.24	-75.77	-296.10
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	-45.91	-22.05	-32.45	17.44	-62.27	-22.31
Net Profit Growth (%)	6.67	-10.50	-40.61	21.38	-77.46	-45.56
EPS Growth (%)	-2.14	0.25	-0.37	-2.13	0.74	-4.81
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Price / Earnings	-0.49	-0.58	-0.88	-0.49	-5.27	-1.06
Price / Book Value	-1.05	3.14	1.20	0.25	2.40	-2.35
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.43	-0.25	-0.07	1.73	-3.33	-1.33
Close Price ($)	1.30	0.49	0.99	1.60	5.54	4.20
High Price ($)	14.28	1.87	2.52	5.92	28.00	16.60
Low Price ($)	0.18	0.44	0.68	1.32	4.20	0.64
Market Cap ($ Cr)	--	--	--	--	--	--

Solvency Ratios	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Debt to Equity	-1.32	--	--	0.05	0.03	-1.19
Short term debt to equity ratio	-1.32	--	--	0.05	0.02	--
Current Ratio	0.34	2.00	6.41	7.18	13.83	1.34
Quick Ratio	0.34	--	--	--	--	--
Interest Coverage	-27.15	--	-42.04	-24.87	-8.33	-10.36

Operating Efficiency Ratios	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	10.40	--	--	--	--	--
Payable days	10,329.23	787.23	1,742.81	2,644,671.76	--	194,686.55
Cash Conversion Cycle	--	--	--	--	--	--